SAB Biotherapeutics, Inc. (SABS) Bundle
An Overview of SAB Biotherapeutics, Inc. (SABS)
An Overview of SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. (SABS) is a clinical-stage biopharmaceutical company founded in 2014, headquartered in Sioux Falls, South Dakota. The company's focus is on developing innovative therapies using its proprietary immunotherapy platform, which leverages large animal immunoglobulin production to create fully human polyclonal antibodies. The primary product candidates are aimed at treating serious diseases, including Type 1 diabetes and COVID-19. As of 2024, SAB Biotherapeutics is advancing its lead product candidate, SAB-142, through clinical trials, targeting autoimmune diseases.
In 2024, SAB Biotherapeutics reported total sales of approximately $1.2 million, a decline from the previous year due to the termination of the Joint Program Executive Office (JPEO) Rapid Response Contract, which had significantly contributed to earlier revenues. The company continues to explore partnerships and licensing opportunities to bolster its product pipeline and revenue streams.
Company's Financial Performance in the Latest Financial Reports
For the nine months ended September 30, 2024, SAB Biotherapeutics reported total revenue of $1,207,712, a decrease of 37.6% compared to $1,933,980 for the same period in 2023. The decline is attributed primarily to the termination of the JPEO Rapid Response Contract, which previously generated substantial revenue for the company. In the third quarter of 2024, the company reported no revenue, down from $1,267,361 in the same quarter of 2023.
Operating expenses for the nine months ended September 30, 2024, totaled $34,109,392, compared to $21,135,529 in 2023, representing an increase of 61.3%. This increase was driven by significant rises in research and development expenses, which amounted to $22,599,998 in 2024, up from $12,217,569 in 2023, marking an 85% increase. General and administrative expenses also rose to $11,509,394, compared to $8,917,960 in 2023, a 29.1% increase.
The net loss for the nine months ended September 30, 2024, was $22,710,610, compared to a loss of $19,337,023 for the same period in 2023. The loss per share attributable to the company's shareholders was $(2.45) for the nine months ended September 30, 2024, compared to $(3.79) for the same period in 2023. The company continues to incur operating losses as it invests heavily in research and development to advance its product candidates.
| Financial Metric | 2024 (9 Months) | 2023 (9 Months) | Change | % Change |
|---|---|---|---|---|
| Total Revenue | $1,207,712 | $1,933,980 | $(726,268) | (37.6%) |
| Operating Expenses | $34,109,392 | $21,135,529 | $12,973,863 | 61.3% |
| Net Loss | $(22,710,610) | $(19,337,023) | $(3,373,587) | 17.4% |
| Loss per Share | $(2.45) | $(3.79) | $1.34 | 35.4% |
Introduction to Company as One of the Leading Companies in the Industry
SAB Biotherapeutics has positioned itself as a leader in the biopharmaceutical industry through its innovative approach to antibody production and its commitment to addressing unmet medical needs. The company's proprietary platform allows for the rapid development of fully human polyclonal antibodies, differentiating it from traditional monoclonal antibody therapies. Despite recent financial challenges, SAB Biotherapeutics continues to invest in its research and development efforts, particularly in its lead candidate SAB-142, which is in clinical trials.
The company is actively seeking partnerships and collaborations to enhance its market presence and leverage its technological advancements. As the biopharmaceutical landscape evolves, SAB Biotherapeutics remains focused on its mission to deliver transformative therapies that improve patient outcomes.
Mission Statement of SAB Biotherapeutics, Inc. (SABS)
Overview of SAB Biotherapeutics, Inc. Mission Statement
The mission statement of SAB Biotherapeutics, Inc. (SABS) serves as a guiding framework for the company’s strategic direction and operational focus. It emphasizes the commitment to leveraging innovative biotherapeutic solutions for the treatment of various diseases, particularly autoimmune disorders and infectious diseases. The mission statement reflects the company's dedication to improving patient outcomes through advanced therapeutic development and emphasizes its role in the biotechnology landscape.
Core Component 1: Innovation
At the heart of SABS's mission is a strong emphasis on innovation. The company strives to develop cutting-edge biotherapeutic products that utilize its proprietary technology platform, which harnesses the immune response of large animals to produce human antibodies. This innovative approach allows for the rapid development of therapies that can address unmet medical needs.
For instance, SABS is focused on its lead product candidate, SAB-142, which is in clinical trials targeting Type 1 diabetes. The company invested approximately $22.6 million in research and development during the first nine months of 2024, reflecting an 85% increase compared to the same period in 2023. This investment underscores the commitment to innovation and the advancement of its therapeutic pipeline.
Core Component 2: Patient-Centric Approach
The second core component of SABS's mission statement is a patient-centric approach. The company prioritizes the needs and well-being of patients in the development of its therapies. This approach is evident in SABS's commitment to conducting rigorous clinical trials and adhering to regulatory standards to ensure safety and efficacy.
In 2024, SABS reported a net loss of $22.7 million for the nine months ended September 30, 2024, primarily due to increased research and development expenses. This financial commitment reflects the priority placed on developing therapies that can significantly impact patient lives, particularly in chronic and debilitating conditions.
Core Component 3: Collaboration and Partnership
The final component of the mission statement emphasizes the importance of collaboration and partnership within the biotechnology ecosystem. SABS actively seeks strategic alliances with other companies, research institutions, and governmental organizations to enhance its research capabilities and expedite the development of its therapeutic candidates.
As part of its collaborative efforts, SABS previously engaged in a significant contract with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, which had a potential value of $203.6 million. However, this contract was terminated in 2022, impacting the company’s revenue streams. Moving forward, SABS aims to explore new partnerships to support its ongoing development projects.
| Financial Metric | 2024 (9 months) | 2023 (9 months) | Change (%) |
|---|---|---|---|
| Total Revenue | $1,207,712 | $1,933,980 | -37.6% |
| Research and Development Expenses | $22,599,998 | $12,217,569 | +85.0% |
| General and Administrative Expenses | $11,509,394 | $8,917,960 | +29.1% |
| Net Loss | $22,710,610 | $19,337,023 | +17.9% |
This table illustrates the financial performance of SABS over the nine months ending September 30, 2024, highlighting the impacts of increased investment in research and development aligned with its mission statement's focus on innovation and patient care.
Vision Statement of SAB Biotherapeutics, Inc. (SABS)
Vision Statement of SAB Biotherapeutics, Inc. (SABS)
The vision statement of SAB Biotherapeutics, Inc. focuses on its commitment to innovation and leadership in the biopharmaceutical industry, particularly in the development of human polyclonal immunotherapeutic antibodies. As of 2024, the company aims to transform healthcare by addressing immune system disorders and infectious diseases through its proprietary technology.
Innovation in TherapeuticsSAB Biotherapeutics strives to be at the forefront of biopharmaceutical innovation. The company’s flagship product, SAB-142, is designed to prevent or delay the progression of Type 1 diabetes. As of September 30, 2024, the company reported research and development expenses amounting to approximately $22.6 million for the nine months ended, reflecting its ongoing investment in innovative therapeutic solutions.
Commitment to Quality and SafetyQuality and safety in product development are critical components of SAB Biotherapeutics’ vision. The company engages in rigorous clinical trials to ensure that its products meet high standards. In December 2023, SAB-142 entered Phase 1 safety studies, overseen by Avance Clinical PTY, Ltd, indicating a systematic approach to clinical validation.
Global ImpactSAB Biotherapeutics envisions making a significant global impact by expanding access to its therapies. The company’s operations include international collaborations, such as its new subsidiary in Australia, SAB BIO PTY LTD, which is focused on qualifying for the Australian government’s tax credit program for research and development activities, potentially enhancing its global reach and financial sustainability.
Financial OverviewAs of September 30, 2024, SAB Biotherapeutics reported total assets of $53.8 million, with $30.4 million in cash and cash equivalents. The company experienced a net loss of $22.7 million for the nine months ended September 30, 2024, which highlights the financial challenges faced while pursuing its ambitious vision.
| Financial Metrics | 2024 (Nine Months Ended September 30) | 2023 (Nine Months Ended September 30) | Change |
|---|---|---|---|
| Research and Development Expenses | $22,599,998 | $12,217,569 | $10,382,429 |
| General and Administrative Expenses | $11,509,394 | $8,917,960 | $2,591,434 |
| Total Revenue | $1,207,712 | $1,933,980 | ($726,268) |
| Net Loss | ($22,710,610) | ($19,337,023) | ($3,373,587) |
Through its vision, SAB Biotherapeutics aims to address pressing health challenges and improve patient outcomes globally, underpinned by its commitment to innovation, quality, and safety in its therapeutic offerings.
Core Values of SAB Biotherapeutics, Inc. (SABS)
Integrity
Integrity is a foundational value at SAB Biotherapeutics, Inc. (SABS). It emphasizes the importance of ethical behavior, transparency, and accountability in all aspects of the company’s operations. This value is vital as it builds trust with stakeholders, including investors, employees, and regulatory bodies.
In 2024, SAB Biotherapeutics demonstrated its commitment to integrity through rigorous compliance with regulatory standards. The company has consistently adhered to the guidelines set forth by the FDA during its clinical trials, specifically for its lead candidate, SAB-142. The transparency in reporting trial results, including both successful and unsuccessful outcomes, showcases the company's dedication to ethical practices.
Innovation
Innovation drives SABS's approach to developing advanced biotherapeutic solutions. The company focuses on creating human polyclonal immunotherapeutic antibodies to address complex immune-mediated disorders and infectious diseases.
As of 2024, SAB Biotherapeutics has invested significantly in research and development, with total R&D expenses amounting to approximately $22.6 million for the nine months ended September 30, 2024, compared to $12.2 million for the same period in 2023. This increase underscores the company's commitment to advancing its product pipeline, including the ongoing clinical trials for SAB-142.
Collaboration
Collaboration is essential for SABS, enabling the company to leverage external expertise and resources. This value fosters partnerships that enhance research capabilities and accelerate the development of therapeutics.
In 2024, SAB Biotherapeutics partnered with Avance Clinical PTY, Ltd to oversee its Phase 1 safety study for SAB-142, which commenced in December 2023. This collaboration allows SABS to utilize Avance's expertise in clinical trial management, thereby improving the efficiency and effectiveness of the trial process.
Excellence
Excellence reflects SABS's commitment to high standards in research, production, and customer service. The company strives for operational efficiency and effectiveness in all its endeavors.
For the nine months ending September 30, 2024, SABS reported total operating expenses of $34.1 million, a significant increase from $21.1 million during the same period in 2023. This investment in operational excellence is aimed at enhancing the quality of its products and services, ensuring that they meet the highest industry standards.
Compassion
Compassion at SABS is reflected in the company's focus on developing therapies that address unmet medical needs. This value drives the company to prioritize patient welfare in its research and development activities.
The lead candidate, SAB-142, specifically targets Type 1 diabetes, a condition that significantly impacts the lives of many individuals. By focusing on this therapy, SABS demonstrates its commitment to improving patient outcomes and addressing critical health challenges.
| Core Value | Description | Examples of Commitment (2024) |
|---|---|---|
| Integrity | Ethical behavior and transparency in operations | Compliance with FDA regulations during clinical trials |
| Innovation | Focus on advanced biotherapeutic solutions | R&D expenses of $22.6 million for nine months ending September 30, 2024 |
| Collaboration | Leveraging external expertise | Partnership with Avance Clinical for Phase 1 study |
| Excellence | High standards in research and production | Total operating expenses of $34.1 million for nine months ending September 30, 2024 |
| Compassion | Focus on unmet medical needs | Development of SAB-142 for Type 1 diabetes |
SAB Biotherapeutics, Inc. (SABS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- SAB Biotherapeutics, Inc. (SABS) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of SAB Biotherapeutics, Inc. (SABS)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View SAB Biotherapeutics, Inc. (SABS)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.